. Author manuscript; available in PMC: 2025 Jun 18.

Published in final edited form as: J Am Coll Cardiol. 2022 Jun 1;80(3):233–250. doi: 10.1016/j.jacc.2022.04.034

Table 5.

Association of urinary TXB₂-M^a with cardiovascular mortality risk when adjusted for relevant predictors of survival.

Model	ASA User (N=1363)			ASA Non-user (N=1680)			All (N=3043)^b
	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
Model 1^c	1.87	1.22, 2.88	0.0043	3.87	2.15, 6.97	<0.0001	2.41	1.71, 3.39	<0.0001
Model 2^d	1.69	1.08, 2.64	0.0219	2.69	1.46, 4.96	0.0015	1.93	1.35, 2.76	0.0003
Model 3^e	1.68	1.06, 2.65	0.0259	3.69	1.95, 6.96	<0.0001	2.11	1.46, 3.06	<0.0001
Model 4^f	1.65	1.02, 2.65	0.0397	3.56	1.92, 6.62	<0.0001	2.13	1.47, 3.09	<0.0001
Model 5^g	1.36	0.77, 2.38	0.2898	2.82	1.39, 5.66	0.0041	1.70	1.10, 2.62	0.0163

Abbreviations: ASA, aspirin; HR, hazard ratio; CI, confidence interval; BMI, body mass index; IL-6, interleukin 6; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate.

Quartile 4 versus quartiles 1–3.

P-value not significant for interaction between ASA use and urinary TXB₂-M in all models.

Unadjusted.

Adjusted for age and sex.

Adjusted for 8-isoPGF_2α, IL-6 and P-selectin. (N=1299 for ASA and N=1600 for non-ASA groups.)

Adjusted for systolic blood pressure, total cholesterol/HDL ratio, current smoking status, BMI and hemoglobin A1_C. (N =1346 for ASA and N=1664 for non-ASA groups.)

Adjusted for age, sex, systolic blood pressure, total cholesterol/HDL ratio, current smoking status, LVEF, hemoglobin A_1C, eGFR and IL-6. (N =1186 for ASA and N=1467 for non-ASA groups.)